Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging

被引:69
作者
Hubbard, JS
Rohrmann, S
Landis, PK
Metter, EJ
Muller, DC
Andres, R
Carter, HB
Platz, EA
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[4] NIA, Clin Invest Lab, Longitudinal Studies Sect, Baltimore, MD 21224 USA
关键词
D O I
10.1016/j.urology.2003.09.060
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To examine the relationship of insulin, glucose, and anthropometry with the subsequent risk of prostate cancer. Methods. The relative risk of prostate cancer by insulin, glucose, and anthropometric measures was evaluated in 823 male participants (87 patients with prostate cancer in 10,737 person-years of follow-up) of the Baltimore Longitudinal Study of Aging who had at least one fasting plasma insulin measurement, which was prediagnostic for those with prostate cancer. Age-adjusted and multivariate-adjusted relative risks were estimated from Cox proportional hazards regression models. Results. Insulin concentrations were in the normal range (defined as less than 20 muU/mL) for 95.1% of participants. Fasting insulin and glucose levels were unrelated to prostate cancer risk in our overall analysis (P for trend = 0.56 and 0.45, respectively). The relative risk of prostate cancer for the second through fourth quartiles of the waist/hip ratio compared with the lowest quartile was 2.10, 1.96, and 2.06, respectively (P for trend = 0.32). Risk was unrelated to waist circumference and body mass index. Conclusions. The results of this study do not conclusively support positive associations of markers of insulin and glucose metabolism and obesity with prostate cancer. Additional larger prospective studies with repeated measure of these parameters are warranted to explore these associations further.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 31 条
[1]   Body fat distribution, insulin resistance, and metabolic diseases [J].
Bjorntorp, P .
NUTRITION, 1997, 13 (09) :795-803
[2]   GEOGRAPHICAL AND TEMPORAL PATTERNS OF INCIDENCE AND MORTALITY FROM PROSTATE-CANCER [J].
BOYLE, P ;
MAISONNEUVE, P ;
NAPALKOV, P .
UROLOGY, 1995, 46 (3A) :47-55
[3]   A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older [J].
Carter, HB .
UROLOGY, 2000, 55 (06) :796-799
[4]   What causes prostate cancer? A brief summary of the epidemiology [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, EL .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (04) :263-273
[5]  
*COMM STAT AM DIAB, 1969, DIABETES, V18, P299
[6]   Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia [J].
Dahle, SE ;
Chokkalingam, AP ;
Gao, YT ;
Deng, J ;
Stanczyk, FZ ;
Hsing, AW .
JOURNAL OF UROLOGY, 2002, 168 (02) :599-604
[7]  
DAVEYSMITH G, 1992, AM J EPIDEMIOL, V136, P1110
[8]   Anthropometric risk factors for prostate cancer [J].
DemarkWahnefried, W ;
Conaway, MR ;
Robertson, CN ;
Mathias, BJ ;
Anderson, EE ;
Paulson, DF .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1997, 28 (03) :302-307
[9]   PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml [J].
Fang, J ;
Metter, EJ ;
Landis, P ;
Carter, HB .
UROLOGY, 2002, 59 (06) :889-893
[10]   Postload plasma glucose concentration and 27-year prostate cancer mortality (United States) [J].
Gapstur, SM ;
Gann, PH ;
Colangelo, LA ;
Barron-Simpson, R ;
Kopp, P ;
Dyer, A ;
Liu, K .
CANCER CAUSES & CONTROL, 2001, 12 (08) :763-772